Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  04:00 2022-12-07 pm EST
2.870 USD   -15.84%
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targets
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Morgan Stanley Downgrades ADC Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $17

09/09/2022 | 08:47am EST


ę MT Newswires 2022
All news about ADC THERAPEUTICS SA
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targe..
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Eq..
MT
11/09BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target t..
MT
11/09RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cam..
MT
11/08Transcript : ADC Therapeutics SA, Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 Revenue $76.3M
MT
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 EPS $0.13
MT
11/08Adc Therapeutics : Purchase Agreement - Form 6-K
PU
More news
Analyst Recommendations on ADC THERAPEUTICS SA
More recommendations
Financials (USD)
Sales 2022 191 M - -
Net income 2022 -164 M - -
Net cash 2022 309 M - -
P/E ratio 2022 -1,37x
Yield 2022 -
Capitalization 229 M 229 M -
EV / Sales 2022 -0,42x
EV / Sales 2023 0,50x
Nbr of Employees 312
Free-Float 46,9%
Chart ADC THERAPEUTICS SA
Duration : Period :
ADC Therapeutics SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADC THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 2,87 $
Average target price 13,86 $
Spread / Average Target 383%
EPS Revisions
Managers and Directors
Ameet Mallik President, Chief Executive Officer & Director
Jennifer Creel Chief Financial Officer
Ron Squarer Chairman
Patrick van Berkel Chief Scientific Officer
Joseph S. Camardo Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ADC THERAPEUTICS SA-83.12%273
VERTEX PHARMACEUTICALS44.63%80 039
REGENERON PHARMACEUTICALS, INC.19.62%79 831
BIONTECH SE-37.31%39 277
WUXI APPTEC CO., LTD.-33.48%32 589
GENMAB A/S23.38%29 957